Difference in substrate specificity between human and mouse lysosomal acid lipase: low affinity for cholesteryl ester in mouse lysosomal acid lipase

Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development

Wolman disease (WD) and cholesteryl ester storage disease (CESD) are lysosomal storage diseases (LSDs) caused by a deficiency in lysosomal acid lipase (LAL) due to mutations in the LIPA gene. This enzyme is critical to the proper degradation of cholesterol in the lysosome. LAL function is completely lost in WD while some residual activity remains in CESD. Both are rare diseases with an incidence rate of less than 1/100,000 births for WD and approximate 2.5/100,000 births for CESD. Clinical manifestation of WD includes hepatosplenomegaly, calcified adrenal glands, severe malabsorption and a failure to thrive. As in CESD, histological analysis of WD tissues reveals the accumulation of triglycerides (TGs) and esterified cholesterol (EC) in cellular lysosomes. However, the clinical presentation of CESD is less severe and more variable than WD. This review is to provide an overview of the disease pathophysiology and the current state of therapeutic development for both of WD and CESD. The review will also discuss the application of patient derived iPSCs for further drug discovery.

Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins

Disorders concerning the metabolism of plasma and intracellular lipids are hallmarks of atherosclerosis. However, failures in proper control of intracellular cholesterol balance, rather than simple cholesterol overloading due to augmented uptake, could fuel atherogenesis. Therefore, the understanding of atherosclerosis-associated lipid alterations, which feed an inflammatory microenvironment in the arterial wall, requires the meticulous investigation of several aspects of lipid synthesis, uptake and export from cells. In this regard, the presence of reactive cysteines in transcription factors and key enzymes of lipid metabolism may dictate cholesterol accumulation, and therefore the progression of vascular disease. The strong inhibitory effect of cysteine-reactant anti-inflammatory cyclopentenone prostaglandins (CP-PGs) over atherosclerosis progression in vivo (LipoCardium technology) symbolizes a new concept of atherosclerosis and its treatment. Results from this laboratory and those from other research groups have unraveled a novel facet in prostaglandin research in that CP-PGs may act as redox signals that guide lipid metabolism in atherosclerosis. By modifying enzymes (e.g., HMG-CoA reductase, ACAT and cholesteryl ester hydrolases) and transcription factors (e.g., NF-kappaB and Keap1) involved in inflammation and lipid metabolism, CP-PGs (especially those of A-series) induce pivotal changes in glutathione and lipid metabolism that completely arrest atherosclerosis progression. Hence, pharmacological manipulation of lipid metabolism by CP-PGs may be a novel and invaluable strategy for treating atherosclerosis. Also, a better understanding of why CP-PGs do not resolve inflammation physiologically may explain many unsolved questions and yield insights into atherogenesis and its termination.

Purification, cloning and regulation of a novel acid-lipase-like protein of hamster expressed in lacrimal glands and tears during lactation

We report a novel 48-kDa tear acid-lipase-like protein (TALLP), which is markedly induced in lacrimal glands (LG) and secreted in tears of hamster dams during lactation. TALLP is undetectable in LG and tears of normal hamsters, but is also induced after gonadectomy in both sexes and this is prevented by androgen, estrogen or thyroid hormone treatment. These observations and the obliteration of TALLP upon cessation of lactation suggest that endogenous estrogens (in females) and androgens (in males) completely repress TALLP expression. Purified TALLP is monomeric, contains approximately 18% N-glycosylation and several pI isoforms. TALLP expression was tissue-specific and immunolocalized in LG acinar cells. The cDNA deduced amino-acid sequence of TALLP precursor (398 residue, containing a 19 residues signal-peptide) showed only 43-48% identity with all known mammalian acid-lipases, including even those of other rodents, suggesting that TALLP is a prototype of a new category, within the acid-lipase family. Surprisingly, although the catalytic triad residues and other sequence features important for lipolytic activity are conserved in TALLP, it has no detectable lipase activity. However, TALLP binds the polarity sensitive hydrophobic probe, 1-aminoanthracene (K(d)=12 microM). TALLP might have a unique substrate-specificity or a lipid-binding/carrier function in tears of hamster dams. This is the first report of an acid-lipase-like protein secreted in tears of any species. Since TALLP lacks the usual lipase activity, it can be an excellent model to understand better what other structural features in acid-lipases influence their catalytic activity.

Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice

Lysosomal acid lipase (LAL) is the essential enzyme for hydrolysis of triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Its deficiency produces two human phenotypes: Wolman disease (WD) and cholesteryl ester storage disease (CESD). The LAL null (lal(-/-)) mouse mimicks aspects of human WD and CESD. The potential for gene therapy of LAL deficiency was tested with first-generation adenoviral vectors containing human LAL cDNA (Ad-hLAL) by intravenous injection into lal(-/-) mice. Compared with phosphate-buffered saline-injected controls, the mice receiving Ad-hLAL had increased hepatic LAL activity, decreased hepatomegaly, and normalization of histopathology. hLAL protein and mRNA were detected by immunohistochemical staining and in situ hybridization in hepatic parenchymal and sinusoid lining cells, splenic sinusoidal cells, lung macrophages, and adrenal cortical cells. Mice showed TG reductions in liver, spleen, and small intestine of 68, 54, and 50%, respectively, and cholesterol reductions of 55, 52, and 34%, respectively, at 20 days postinjection. These studies provide the basis for the use of gene therapy, in the form of gene transfer via intravenously administered adenovirus, to correct deficiency states, such as WD and CESD, and histopathology of a variety of tissues.